To further confirm the germline MSH2 status and study the genomic profiling of tumors, we performed targeted sequencing on her peripheral blood leucocytes, paraffin sections of her 2020 ureteral cancer sample and the 2023 colon cancer sample using the HapOnco StarPanel NGS Assay (HaploX Biotechnology, Shenzhen). This evidence concerns the gene MSH2 and malignant colon neoplasm.